# Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial

> **NCT07721363** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 65 (estimated)

## Conditions studied

- Lupus Nephritis
- Membranous Nephropathy

## Interventions

- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT07721363
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-02
- **Primary completion:** 2029-09-02
- **Final completion:** 2029-09-02
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07721363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07721363, "Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07721363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*